ArticleInternational journal of biomaterials2026
Effect of Genipin Crosslinking on the Cellular Delivery of Gelatin Nanocarriers Using Curcumin as a Payload.
Article in International journal of biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of Genipin Crosslinking on the Cellular Delivery of Gelatin Nanocarriers Using Curcumin as a Payload.International journal of biomaterials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gelatin-based nanoformulations have received special attention for drug delivery applications because of their regulatory acceptability. A thorough understanding of the factors controlling the interaction of gelatin nanocarriers with cellular systems is crucial for their future biomedical applications. The present study addresses the effect of genipin crosslinking on the ability of gelatin nanoparticles (GNPs) to deliver curcumin, a pharmacologically active ingredient from turmeric into lung cancer (A549) cells. Briefly, the methodology was optimized to prepare GNP (15 mg/mL) crosslinked with 0.25, 0.5, and 1.0 mg/mL of genipin (GN-GNP1-3, respectively). The crosslinking of GN-GNP1-3 was established through UV-VIS, Fourier transform infrared spectroscopy, and circular dichroism measurements. Dynamic light scattering and transmission electron microscopy showed nearly identical hydrodynamic size (165 ± 15 nm) and shape (spherical) for GN-GNP1-3. Subsequently, these nanocarriers were loaded with curcumin and evaluated for drug delivery properties (loading efficiency and release kinetics), cellular uptake, cytotoxicity, and associated mechanisms. These studies together revealed that GN-GNP1-3 of increasing degree of crosslinking exhibited higher curcumin loading efficiency, facilitated slow and sustained release of curcumin over a prolonged period (80 h) by a non-Fickian mechanism, and ultimately increased the cellular uptake and the effectiveness (or cytotoxicity) of entrapped curcumin in A549 cells. The pharmacological abrogation investigations established that curcumin-loaded GN-GNP3 was internalized within A549 cells through caveolae-mediated endocytosis. In conclusion, genipin crosslinking of gelatin-based nanocarriers seemed to be a novel strategy to increase the cellular uptake cum effectiveness of a hydrophobic payload like curcumin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.